Jefferies Global Health Care Conference. June 1, 2015
|
|
- Martin Flowers
- 6 years ago
- Views:
Transcription
1 Jefferies Global Health Care Conference June 1, 2015
2 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and uncertainties, including those discussed in the press release issued today and in the Company s filings with the Securities and Exchange Commission. While this presentation represents management s current judgment on the future direction of the Company s business, such risks and uncertainties could cause actual results to differ materially from any future performance suggested herein. The Company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. 2
3 Fully Integrated Service Platform Spans Drug Development Spectrum from Discovery to Manufacturing Target Discovery Lead Finding Lead Optimization Candidate Selection Pre-Clinical Phase I Phase 2 Phase 3 Product Approval Generic R&D ANDA Development & Approval Discovery & Development Services (DDS) Recognized experts in medicinal and solid state chemistry Flexible, competitive cost structure Development services growing rapidly 2015 Forecast*: $98M API Manufacturing Focusing on high value, niche APIs; brands and high value generics Controlled substances, steroids, proteins, peptides and cytotoxics 2015 Forecast*: $162M Drug Product Manufacturing Focusing on high value, technically challenging areas End-to-end sterile fill/finish capabilities 2015 Forecast*: $92M 3 *Represents mid point of guidance as of May 5, 2015
4 Key Milestones Last Twelve Months Completed and integrated 4 acquisitions Cedarburg API, controlled substances OsoBio Commercial scale sterile injectable manufacturing SSCI/West Lafayette Supplementing development capabilities with physical chemistry, polymorph and DMPK expertise Glasgow, UK Pre-formulation/small scale sterile injectable development Established differentiated, integrated discovery center in Buffalo Advanced growth in generics with multiple development programs across all segments, capturing development, commercial and royalty revenue potential Added key strategic positions in supply chain, IT and international sales Creating sustainable shareholder value by replacing declining royalties with profitable contract business 4 4
5 Entering a New Growth Era as Outsourcing Trends Increase Global pharma simplifying to core competencies Reducing internal resources Generic competition Divesting assets; Reducing fixed cost structures Vendor consolidation programs benefitting integrated providers Early to mid-stage companies accessing outsourcing VCs / Academia / Virtual pharma Increased funding fueling increase in early discovery and development Industry consolidation triggering interest in larger outsourcing partners 5
6 Drug Product API Pipeline of Development and Commercial Contracts Expanding Rapidly Development Supporting these Programs Phase I & II Phase III 505b/ANDAs Commercial 6
7 Q Financial Highlights ($ in millions, except per share amounts) Q Q Growth Y/Y Contract Revenue $75.1 $ % Royalties $6.7 $8.3 (19%) Total Revenue $81.8 $ % Adj. Cost of Contract Revenue* $57.9 $ % Adj. SG&A as a % of Revenue* 18% 19% (1) PPT Adjusted EBITDA* $14.5 $ % Non-GAAP EPS* $0.20 $ % Tax Rate 35.0% 29.1% 6 PPT Adjusted Contract Margin Q Q % 18% 7 *Please refer to tables at the end of the presentation for a reconciliation of non-gaap items
8 Contract Revenue Up 47% Q1 Y/Y ($ in millions) Contract Revenue +47% vs. Q
9 Adjusted EPS Q Q ¹See tables at the end of the presentation for a reconciliation of GAAP EPS to non-gaap EPS.
10 Contract Revenue Projected to Increase Over 40% from $400 $350 $353 $300 $250 $251 $200 $150 $144 $122 $137 $153 $163 $195 $157 $163 $170 $190 $210 $100 $50 $60 $72 $ *2015E 10 *Represents mid point of guidance as of May 5, 2015 DDS API Drug Product Q1 Actual Q2 Q4 Estimate
11 Sustainable Contract Operating Income Offsetting Declining Royalties Operating Income (Ex. Royalties) Royalties Contract Operating Margin % Current (Ex. Royalties) 11 *Represents mid-point of guidance as of May 5, **See tables at the end of the presentation for a reconciliation of GAAP EPS to non-gaap EPS.
12 Strategic Priorities for 2015 Disciplined Capital Deployment Organic Growth Acquisitions Invest in core areas to fuel growth in discovery, development and manufacturing Add capabilities that complement our existing core areas DDS Integrate chemistry and biology in Buffalo API Expand generic portfolio and global footprint Drug Product Increase scale to take advantage of growing market needs Enhance operational efficiencies/integrate AMRI Scope and begin ERP implementation Holywell site transition and closure A Disciplined Deployment of Capital Will Fuel Growth and Shareholder Value 12
13 Thank You
14 Appendix
15 DDS Performance 1Q 2015 ($ in millions) Q Q % Change Y/Y DDS Contract Revenue $19.3 $19.0 1% Cost of Contract Revenue $14.8 $15.6 (6%) Contract Gross Profit $4.5 $3.4 32% Contract Gross Margin 23% 18% 5 PPT Q Contract Revenue: $19.3M, up 1% Operational efficiency programs delivering enhanced margins SSCI on track with integration Initiating development work as part of 10-year NIH award Expanded API & Drug Product capabilities and capacity increasing demand for Development services Supporting development of 67 APIs and 99 Drug Product formulations 15
16 API Performance - 1Q 2015 ($ in millions) Q Q % Change Y/Y API Contract Revenue $37.8 $ % Cost of Contract Revenue $28.6 $ % Contract Gross Profit $9.3 $6.5 43% Contract Gross Margin 25% 22% 3 PPT Q Contract Revenue: $37.8M, up 27% Advancing growth in generics with multiple development programs Expanding controlled substance portfolio Long term supply agreements for commercial business 53 commercial products being manufactured Multiple late stage products and scalable infrastructure for future growth 48 Phase I & II Compounds 13 Phase III Compounds 6-505b2 or ANDAs 16
17 Drug Product Performance - 1Q 2015 ($ in millions) Q Q % Change Y/Y DP Contract Revenue $18.0 $ % Cost of Contract Revenue $14.8 $ % Contract Gross Profit $3.2 $(0.5) 740% Contract Gross Margin 19% (20%) 39 PPT Q Contract Revenue: $18M, up 688% Reflects addition of OsoBio and Glasgow, UK Gained 7 new customers 1Q Expansion of Drug Product leading to increased development projects 14 Commercial Products 29 Products in Phase III 58 Products in Phase I & II b2 or ANDAs 17
18 Contract Revenue Projected to Increase Over 40% in 2015 ($ in millions) Contract Revenue +41% vs *Represents mid-point of guidance as of May 5, 2015
19 2015 Forecast* ($ in millions, except per share amounts) 2015 Y/Y DDS $98 30% API $162 11% Drug Product $92 210% Contract Revenue $ % Royalties $ % Total Revenue $ % Adjusted Contract Margins 25% 6 PPT Adjusted EBITDA $ % Non-GAAP EPS $ $ % 19 *Represents mid-point of guidance as of May 5, See tables at the end of the presentation for a reconciliation of GAAP EPS to non-gaap EPS.
20 About AMRI Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cgmp manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal). Contacts: Investor Relations: Patty Eisenhaur, AMRI Investor Relations, Media: Gina Rothe, AMRI Communications,
21 Fully Integrated Service Platform Spans Drug Development Spectrum from Discovery to Manufacturing Target Discovery Lead Finding Lead Optimization Candidate Selection Pre-Clinical Phase I Phase 2 Phase 3 Product Approval Generic R&D ANDA Development & Approval Discovery and Development Services (DDS) Hit to Lead to Candidate Services Medicinal Chemistry High Throughput Screening In Vitro Biology and Pharmacology Library Design & Custom Synthesis Biocatalysis and Biotransformation Natural Product Libraries Profiling & Structure ID Bioprocess Development Early ADME Metabolite ID Process and Analytical Development Kilo Lab Scale-Up Phase I GMP Salt & Polymorph Investigations Formulation Development API Manufacturing Phase II/III API Commercial API High Value Intermediates High Potency DEA Regulated API Complex API R&D Global Regulatory Niche Generics Drug Product Manufacturing Top 10 US Fill/Finish Manufacturer Formulation Manufacturing Pre-formulation 21
22 Focused on Higher Growth Segments of Discovery/Development Market $25.0 $ in billions Worldwide CRO Discovery / Preclinical Outlook $20.0 $15.0 $10.0 $5.0 $0.0 $9.9 $9.2 $1.9 $2.2 $0.5 $0.5 $2.5 $2.7 $11.1 $12.8 $3.0 $2.6 $0.6 $0.5 $3.8 $3.2 $2.4 $2.8 $1.5 $1.8 $2.0 $15.8 $14.2 $19.7 $17.6 $5.3 $4.7 $3.9 $0.8 $3.5 $0.7 $0.7 $0.6 $5.9 $5.2 $4.7 $4.2 $3.5 $4.0 $3.1 $2.9 $2.7 $2.8 $3.0 $3.1 $3.4 $3.6 $ CAGR % 6% 13% 15% 4% Safety & Tox Lead Pharmacology Early Chemistry HTS Biology 1 22 Source: Kalorama; McKinsey analysis. ¹ High throughput screening.
23 The API Environment Next 5 Years Market Characteristics Global pharmaceutical market to grow from ~$825B to ~$1,000B by Generics driving growth US is growing 5%; 87% of prescriptions generic Japan expected to be at only 31% generics in 2015 Europe is less than 40% generic; branded generics Branded and Generic Drug Market Global Spending (US$, Billions) $1,200 ROW 6.8% CAGR to $62B $1,000 Emerging 16.2% CAGR to $234B $800 Developed 16.7% CAGR to $121B $600 $400 Branded 1.2% CAGR to $631B Branded $594B $200 Trend of outsourcing of API manufacturing by pharmaceutical companies continues Branded companies moving towards core competencies API manufacturing is a different business; some are divesting assets or minimizing efforts Recent record of 41 branded products approved in $ Developed Emerging ROW 23 ¹ Source: IMS Market Research. 2 Source: FDA
24 Earnings Per Share Reconciliation (Dollars in thousands, except for per share data) Non-GAAP Measures First Quarter First Quarter (Dollars in thousands, except for per share data) Non-GAAP Measures Earnings per diluted share, as reported $ (0.07) $ 0.11 Adjustments, net of tax: Impairment charges Restructuring charges Executive transition costs Business acquisition costs Purchase accounting depreciation and amortization Postretirement benefit plan settlement gain - (0.03) Non-recurring professional fees Debt interest and amortization charges Earnings per diluted share, as adjusted $ 0.20 $
25 EBITDA Reconciliation (Dollars in thousands, except for per share data) Non-GAAP Measures First Quarter 2015 First Quarter 2014 Income from operations, as reported $ 1,229 $ 7,465 Impairment charges 2,615 - Restructuring charges 1, Executive transition costs 1, Business acquisition costs 1, Purchase accounting depreciation and amortization 1,003 - Postretirement benefit plan settlement gain - (1,285) ERP Implementation costs Non-recurring professional fees Income from operations, as adjusted $ 9,570 $ 7,372 Add: Non-operating (expense) income net, as reported 469 (40) Add: Depreciation and amortization 4,483 3,761 Adjusted EBITDA $ 14,522 11,093 25
A full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationCharles River to Acquire WIL Research Charles River Laboratories International, Inc.
Charles River to Acquire WIL Research 2016 Charles River Laboratories International, Inc. Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCalix Q Financial Results. February 13, 2018
Calix Q4 2017 Financial Results February 13, 2018 Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements
More informationWESCO International. Dave Schulz, Senior Vice President and Chief Financial Officer Raymond James 39 th Annual Investors Conference, March 7, 2018
WESCO International Dave Schulz, Senior Vice President and Chief Financial Officer 2 Safe Harbor Statement All statements made herein that are not historical facts should be considered as forward-looking
More informationStericycle, Inc. Q NASDAQ: SRCL
Stericycle, Inc. Q1 2015 NASDAQ: SRCL Forward - Looking Statements This presentation may contain forward-looking statements that involve a number of risks and uncertainties and our actual results could
More informationTrex Company Investor Presentation. May 2017
Trex Company Investor Presentation May 2017 1 Safe Harbor / Non-GAAP Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationAvery Dennison Investor Presentation August 2014
Avery Dennison Investor Presentation August 2014 Unless otherwise indicated, the discussion of the company s results is focused on its continuing operations, and comparisons are to the same period in the
More informationLuc Gregoire Chief Financial Officer. Drexel Hamilton Annual Telecom, Media and Technology Conference September 6, 2017
Luc Gregoire Chief Financial Officer Drexel Hamilton Annual Telecom, Media and Technology Conference September 6, 2017 Forward Looking Statements This presentation and oral statements made from time to
More informationFinancial Objectives. Forward Looking Statements. Symantec 2012 Financial Analyst Day 5/24/2012. James Beer. EVP & Chief Financial Officer
Financial Objectives James Beer EVP & Chief Financial Officer 1 Forward Looking Statements This presentation contains statements regarding our projected financial and business results, which may be considered
More informationJEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationCommerceHub Investor Presentation
CommerceHub Investor Presentation Winter 2017-2018 1 FORWARD-LOOKING INFORMATION This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationInvestor Presentation
Investor Presentation As of August 2, 2017 Advanced Signal Processing Products Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation contain
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationJP Morgan Global Healthcare Conference
JP Morgan Global Healthcare Conference January 12, 2016 Robert Friel, Chairman and CEO Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationINVESTOR PRESENTATION THIRD QUARTER 2016 SAJAN.COM PUBLIC DOCUMENT SAJAN, INC NASDAQ: SAJA
INVESTOR PRESENTATION THIRD QUARTER 2016 SAFE HARBOR The Private Securities Litigation Reform Act of 1995 provides a safe harbor from liability for certain forward-looking statements. This presentation
More informationWILLIAM BLAIR GROWTH STOCK CONFERENCE. June 14, 2017
WILLIAM BLAIR GROWTH STOCK CONFERENCE June 14, 2017 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and are subject
More informationNon Deal Roadshow - Europe
Non Deal Roadshow - Europe 2015 May Analyst Meeting February/March 2016 The world leader in serving science The world leader in serving science Non-GAAP Measures This presentation contains certain financial
More informationWuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014
WuXi PharmaTech: Building an Open-Access Capability and Technology Platform Jefferies Healthcare Conference November 2014 Cautionary Note Regarding Forward-Looking Statements This presentation contains
More informationIBM 4Q 2016 Earnings. January 19, ibm.com/investor
IBM 4Q 2016 Earnings January 19, 2017 ibm.com/investor Forward Looking Statements and Non-GAAP Information 2 Certain comments made in this presentation may be characterized as forward looking under the
More informationFresenius Investor News
health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationR1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business
R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business Investor Presentation February 26, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More information2014 First Quarter Business Review
2014 First Quarter Business Review (unaudited) April 24, 2014 2014 First Quarter Business Review Forward Looking Statements This presentation contains forward-looking information about 3M's financial results
More informationMoberg Pharma AB. Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES
Moberg Pharma AB Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES Conference call, August 9, 2016 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 426 95, US: +1 646 502 51
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationLogitech Q1 Fiscal Year 2015 Preliminary Financial Results Management s Prepared Remarks (July 23, 2014)
Logitech is posting a copy of these prepared remarks, its press release and accompanying slides to its investor website. These prepared remarks will not be read on the call. We refer both to GAAP and to
More informationAgilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me
More informationKeysight Technologies Investor Presentation. December 2017
Keysight Technologies Investor Presentation December 2017 Page 1 Safe Harbor This communication contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the
More informationCautionary Note Regarding Forward Looking Statements
If(we) Acquisition Cautionary Note Regarding Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationBruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life
Bruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life Innovation with Integrity BRUKER CORPORATION Safe Harbor Statement
More informationBrightcove Inc. Investor Presentation. May 2017
Brightcove Inc. Investor Presentation May 2017 Safe Harbor Statement These slides and the accompanying oral presentation contain certain forward-looking statements" within the meaning of the Private Securities
More informationRockwell Automation Company Overview January 2017
Rockwell Automation Company Overview January 2017 2 Safe Harbor Statement This presentation includes statements related to the expected future results of the company and are therefore forward-looking statements.
More informationFresenius Investor News
health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationSecond Quarter 2017 Earnings Teleconference. August 1, 2017
Second Quarter 2017 Earnings Teleconference August 1, 2017 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information 3 Our discussions
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationTriNet Group, Inc. William Blair Growth Company Conference June 2017
TriNet Group, Inc. William Blair Growth Company Conference June 2017 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationFirst Quarter FY18 First Fiscal Quarter Financial Results FY18 Financial Results May 31, 2017
First Quarter FY18 First Fiscal Quarter Financial Results FY18 Financial Results May 31, 2017 Put a date here. Or May the speaker s 31, 2017 name. Or their @handle Forward-Looking Statements and Non-GAAP
More informationPhilips: a focused leader in HealthTech
Philips: a focused leader in HealthTech Frans van Houten, CEO Royal Philips 36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA January 9, 2018 Important information Forward looking statements
More informationMorgan Stanley Conference. November 15, 2017
Morgan Stanley Conference November 15, 2017 1 Forward Looking Statements Certain statements in this release or presentation, other than purely historical information, including estimates, projections,
More informationThe Timely Rise of the CDMO
OneSource Simplicity and speed. Delivered. The Timely Rise of the CDMO The healthcare sector can improve its margins by tens of billions of dollars and improve patient safety by making supply chain improvements.
More informationLas Vegas Sands Corp. Reports Landmark Fourth Quarter and Full Year 2011 Results
Las Vegas Sands Corp. Reports Landmark Fourth Quarter and Full Year 2011 Results Declares Annual Dividend of $1.00 per Share; Fourth Quarter Net Revenue Increases 26.3% to Record $2.54 Billion; Fourth
More informationCitigroup Global Industrial Manufacturing Conference March 6, 2007
Citigroup Global Industrial Manufacturing Conference March 6, 2007 Forward Looking Statements & Non-GAAP Measures The following presentation contains forward-looking information based on TEREX s current
More informationBusiness Outcome Led, Technology Enabled
Business Outcome Led, Technology Enabled Safe-Harbor Statement Statements in this presentation and remarks and responses made in connection with this presentation include forward-looking statements that
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationTriNet Group, Inc. Investor Presentation November 2017
TriNet Group, Inc. Investor Presentation November 2017 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements that are not
More informationDun & Bradstreet Company Overview. JP Morgan Investor Conference November 14, 2017
Dun & Bradstreet Company Overview JP Morgan Investor Conference November 14, 2017 Forward Looking Statement and Use of Non-GAAP Information The contents of this presentation and our related discussion
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationGood afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the
1 Good afternoon, welcome to our annual shareholder meeting. I am Lee Rudow, President and CEO of Transcat and I will provide an overview of the current state of Transcat an our direction for FY17 and
More informationGood day, ladies and gentlemen. Welcome to today s conference call to discuss Stratasys third quarter 2017 financial results.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 SSYS Q3 2017 Earnings Script SLIDE 1 & 2: TITLE SLIDES SPEAKER:
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationCHECKPOINT SYSTEMS, INC. INVESTOR PRESENTATION June 2013
CHECKPOINT SYSTEMS, INC. INVESTOR PRESENTATION June 2013 Global Reach Powerful Partnerships FORWARD-LOOKING STATEMENT This presentation includes information that constitutes forward-looking statements.
More informationThe Growth Strategy of Shionogi. September, 2011
The Growth Strategy of Shionogi September, 2011 Forward-Looking Statements This presentation contains forward-looking statements. These statements are based on expectations in light of the information
More informationEMEA MARKET MARKETING HEIDI ARKINSTALL CMO. RENE OEHLERKING Jaybird. UJESH DESAI GM, Gaming
EMEA MARKET MARKETING HEIDI ARKINSTALL CMO RENE OEHLERKING Jaybird UJESH DESAI GM, Gaming FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the U.S.
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationCB&I Investor Presentation March 2017
A World of Solutions CB&I Investor Presentation March 2017 A Leading Provider of Technology and Infrastructure for the Energy Industry Safe Harbor Statement This presentation contains forward-looking statements
More informationBemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference
Bemis Company, Inc. KeyBanc Capital Markets Basic Materials & Packaging Conference September 14, 2011 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the
More informationCerner Corporation First Quarter 2018 Earnings Conference Call May 2, 2018
Moderator Cerner Corporation First Quarter 2018 Earnings Conference Call May 2, 2018 Welcome to Cerner Corporation s first quarter 2018 conference call. Today s date is May 2, 2018, and this call is being
More informationLas Vegas Sands Corp. Reports Fourth Quarter and Full Year 2010 Results
Las Vegas Sands Corp. Reports Fourth Quarter and Full Year 2010 Results LAS VEGAS, NV -- (MARKET WIRE) -- 02/03/11 -- Las Vegas Sands Corp. (NYSE: LVS) For the Fourth Quarter Ended December 31, 2010: --
More informationLas Vegas Sands Corp. Reports Third Quarter 2010 Results
Las Vegas Sands Corp. Reports Third Quarter 2010 Results Consolidated Third Quarter Adjusted Property EBITDA Increases 136.9% to Record $645.2 Million on Record Net Revenue of $1.91 Billion; Majority-Owned
More informationTECHNOLOGY INNOVATION SOLUTIONS. Investor Presentation
Investor Presentation January 2016 Forward-looking Statements & Non-GAAP Financial Information Forward-Looking Language This presentation and all publicly available documents, including the documents incorporated
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationInvestor Update Q Rob LoCascio CEO Dan Murphy CFO
Investor Update Q4 2017 Rob LoCascio CEO Dan Murphy CFO Safe Harbor Provision Statements in this presentation regarding LivePerson that are not historical facts are forward-looking statements and are subject
More informationPiramal Enterprises Limited. Pharma Strategy 31 st Jan 2017
Piramal Enterprises Limited Pharma Strategy 31 st Jan 2017 Pharma business portfolio with strong presence both within and outside India Piramal Pharma FY16 Rev: Rs.3,558 Crores Global Pharma FY16 Rev:
More informationSecurities Analyst Meeting 2017 PRINTING. Enrique Lores President, Imaging and Printing Business
Securities Analyst Meeting 2017 PRINTING Enrique Lores President, Imaging and Printing Business Forward-looking statements Today s presentations contain forward-looking statements that involve risks, uncertainties
More informationFedEx Corp. Reports First Quarter Earnings FedEx Express Announces 2010 Rate Increase
1 FOR IMMEDIATE RELEASE FedEx Corp. Reports First Quarter Earnings FedEx Express Announces 2010 Rate Increase MEMPHIS, Tenn., September 17, 2009... FedEx Corp. (NYSE: FDX) today reported earnings of $0.58
More informationFresenius Investor News
health care worldwide February 22, 2007 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationFinancial and other information related to the intended combination of Intrum Justitia and Lindorff published by Intrum Justitia
Stockholm 12 June 08:10 CET (page 1 of 5) PRESS RELEASE Intrum Justitia AB (publ) Corporate identity no.:556607-7581 Financial and other information related to the intended combination of Intrum Justitia
More informationSales and net income reach all-time highs 6% dividend increase proposed Positive Group outlook for 2015
Investor News February 25, 205 Birgit Grund Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 6352 Bad Homburg Germany T +49 672 608-2485 F +49 672 608-2488 birgit.grund@fresenius.com
More informationLA-Z-BOY INCORPORATED
LA-Z-BOY INCORPORATED February 2018 Providing comfort to America for 90 years FORWARD-LOOKING DISCLAIMER This presentation contains forward-looking statements that involve uncertainties and risks as detailed
More informationAvnet, Inc. Corporate Overview. As of December 6, 2016
Avnet, Inc. Corporate Overview As of December 6, 2016 1 December 6, 2016 From components to cloud and design to disposal, Avnet brings products, services and solutions to customers that build, sell and
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationBank of America Merrill Lynch
Bank of America Merrill Lynch 2017 Global Energy Conference November 16-17, 2017 Forward-Looking Statements This material and any oral statements made in connection with this material include "forwardlooking
More informationA Technology Solutions and Business Services Company
A Technology Solutions and Business Services Company Fiscal Fourth Quarter, Ended November 30, 2017 Safe Harbor Statement Statements in this presentation regarding SYNNEX Corporation which are not historical
More informationFedEx Corp. Reports Strong Earnings Growth
FOR IMMEDIATE RELEASE FedEx Corp. Reports Strong Earnings Growth MEMPHIS, Tenn., December 17, 2014... FedEx Corp. (NYSE: FDX) today reported earnings of $2.14 per diluted share for the second quarter ended
More informationAcquisition of Amplify Snack Brands, Inc. December 18, 2017
Acquisition of Amplify Snack Brands, Inc. December 18, 2017 1 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. Many of these forward-looking statements can be identified
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationPayPal Reports First Quarter 2017 Results and Raises Financial Guidance for Full Year
PayPal Reports First Quarter 2017 Results and Raises Financial Guidance for Full Year Q1 GAAP EPS increased 6% to $0.32, non GAAP EPS increased 19% to $0.44 $5 billion stock repurchase authorization announced
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationRedefining Travel Commerce. Bernstein Strategic Decisions Conference 2016
Redefining Travel Commerce Bernstein Strategic Decisions Conference 2016 Disclaimers Related to Forward-Looking Statements Certain items in this presentation and in today s discussion, including matters
More informationInge Thulin. Chairman of the Board, President and CEO. Bernstein Strategic Decisions Conference. June 1, 2017
Inge Thulin Chairman of the Board, President and CEO Bernstein Strategic Decisions Conference June 1, 2017 1 Forward looking statement This presentation contains forward-looking information about 3M's
More informationLetter to Shareholders Q2 FY18
November 2, 2017 Letter to Shareholders Q2 FY18 CIRRUS LOGIC, INC. 800 WEST SIXTH STREET, AUSTIN, TEXAS 78701 November 2, 2017 Dear Shareholders, Cirrus Logic reported outstanding results in the September
More informationFedEx Corporation Investor Relations February 12, 2018
FedEx Corporation Investor Relations February 12, 2018 Forward-Looking Statements Certain statements in this presentation may be considered forward-looking statements, such as statements relating to management
More informationNord Anglia Education Second Quarter Fiscal 2014 Results Presentation. April 23, 2014
Nord Anglia Education Second Quarter Fiscal 2014 Results Presentation April 23, 2014 For the period ended February 28, 2014 Disclaimer Neither Nord Anglia Education Inc. nor any of its subsidiaries or
More informationFresenius Medical Care and Fresenius Kabi confirm guidance for 2009, Fresenius Helios and Fresenius Vamed raise their outlook
Press Release August 4, 2009 Joachim Weith Senior Vice President Corporate Communications and Public Affairs Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2101 F +49 6172 608-2294
More informationConference Call FY/17 Results
Conference Call FY/17 Results Bad Homburg, 27 February 2018 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking
More informationTalend Investor Relations Presentation August 25, 2016
Talend Investor Relations Presentation August 25, 2016 2016 Talend SA 1 This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements
More informationALASTAIR CURTIS Chief Design Officer. CHARLOTTE JOHS GM, Ultimate Ears
DESIGN ALASTAIR CURTIS Chief Design Officer CHARLOTTE JOHS GM, Ultimate Ears FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the U.S. federal securities
More informationExcellent sales and earnings growth Earnings outlook raised
Press Release August 3, 2010 Matthias Link Corporate Communications Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2872 F +49 6172 608-2294 Matthias.Link@fresenius.com www.fresenius.com
More informationFresenius Investor News
Analysts Meeting and Live video webcast today Fresenius Medical Care at 2.30 p.m. CET / 8.30 a.m. EDT Fresenius AG at 4.30 p.m. CET / 10.30 a.m. EDT health care worldwide May 4, 2005 Contact: Birgit Grund
More informationirobot First-Quarter 2017 Conference Call Script
irobot First-Quarter 2017 Conference Call Script Operator: Good day everyone and welcome to the irobot first-quarter 2017 financial results conference call. This call is being recorded. At this time for
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation September 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.4% With a Global Footprint Revenue
More informationDassault Systèmes. Analyst Meeting Q308. Bernard Charles, President and CEO Thibault de Tersant, Senior EVP and CFO
Dassault Systèmes Analyst Meeting Q308 Bernard Charles, President and CEO Thibault de Tersant, Senior EVP and CFO Forward Looking Information Statements herein that are not historical facts but express
More informationAnnual General Meeting of Lassonde Industries Inc. May 15, Financial Results for Fiscal 2011 and First Quarter 2012
Annual General Meeting of Lassonde Industries Inc. May 15, 2012 Financial Results for Fiscal 2011 and First Quarter 2012 Highlights Fiscal 2011: Earnings In millions of $ (except EPS) Years ended December
More information